Does Anthem (Elevance Health) Cover Jatenzo?

What Is Jatenzo and Why Does Coverage Get Complicated?

Jatenzo is the first FDA-approved oral testosterone replacement therapy designed to be taken with food, using a self-emulsifying drug delivery system that absorbs through intestinal lymphatics rather than first-pass hepatic metabolism. The FDA approved it in March 2019 for adult men with conditions associated with a deficiency or absence of endogenous testosterone, specifically primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) [1]. Because Jatenzo is a branded, single-source product with a list price near $900 per month, insurers including Anthem classify it as a non-preferred brand and apply prior authorization filters to confirm medical necessity before paying [2].

The clinical rationale for Jatenzo rests on solid data. In the key Phase 3 trial by Swerdloff et al. (J Clin Endocrinol Metab 2020, N=137), 87% of hypogonadal men achieved average total testosterone concentrations within the normal range (300 to 1 to 000 ng/dL) at steady state using twice-daily oral testosterone undecanoate dosed with meals [3]. The same study documented that dose titration at weeks 3 and 7 kept the majority of participants in range without clinically significant elevations in hepatic enzymes, a historical concern with older oral 17-alpha-alkylated androgens [3]. Despite this safety differentiation from methyltestosterone, Anthem's pharmacy benefit managers still require prescribers to justify why a lower-cost option cannot be used first.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends confirming hypogonadism with at least two morning total testosterone measurements below 300 ng/dL before initiating any testosterone formulation [4]. Anthem's PA criteria mirror that threshold almost exactly, so a chart that already contains two timed lab values simplifies authorization considerably.

Anthem Prior Authorization Criteria for Jatenzo

Anthem requires a completed PA request before dispensing Jatenzo at the covered benefit rate. The core clinical elements Anthem reviewers examine follow a consistent pattern across commercial plan lines.

The prescriber must document: (1) a confirmed diagnosis of male hypogonadism supported by two fasting morning serum total testosterone values <300 ng/dL drawn on separate days, (2) the specific hypogonadism subtype (primary versus hypogonadotropic) with supporting labs such as LH and FSH, (3) the presence of signs or symptoms consistent with testosterone deficiency such as reduced libido, fatigue, or reduced bone mineral density per relevant clinical guidelines [4], and (4) confirmation that the patient is an adult male. Some Anthem plan variants also require a note from a urologist or endocrinologist, particularly for employer-sponsored plans with tiered specialist requirements [5].

Step therapy is the most common sticking point. Most Anthem commercial formularies require a documented trial of at least one preferred testosterone agent before Jatenzo is approved. Generic testosterone cypionate 200 mg/mL injection and testosterone topical gel 1.62% (generic) are the two agents most frequently cited as required step agents because both have generic equivalents priced well below Jatenzo's $900 monthly cost [6]. The required trial duration is typically 30 to 90 days, though plans may waive step therapy if the patient has a documented contraindication to injections (such as a bleeding disorder) or a documented adverse reaction to topical formulations (such as skin irritation or transfer risk to a partner or child) [7].

HealthRX Prior Authorization Preparation Checklist for Jatenzo:

1. Pull two morning serum total testosterone labs (both <300 ng/dL, drawn at least one week apart).
2. Add LH and FSH to classify subtype. Low or normal LH with low testosterone supports hypogonadotropic; elevated LH supports primary.
3. Document at least two clinical symptoms from the Androgen Deficiency in Aging Males (ADAM) questionnaire or equivalent.
4. If topicals were tried: record start date, stop date, reason discontinued (skin reaction, transfer concern, compliance difficulty).
5. If injections were tried: record same details plus any needle-phobia documentation or coagulopathy labs if applicable.
6. Attach the Jatenzo FDA-approved prescribing information to the clinical notes submitted with the PA [1].
7. Request peer-to-peer review proactively if any element of the file is incomplete.

How to Submit the Prior Authorization to Anthem

Anthem accepts PA requests through its provider portal at Availity or by fax using the standard PA request form. For Jatenzo specifically, submitting through the electronic portal typically generates a decision within 3 to 5 business days for standard requests [8]. Urgent clinical situations, defined as circumstances where a delay would seriously harm the patient, must be reviewed within 72 hours under NCQA utilization management standards and applicable state laws [8].

Including a peer-reviewed clinical reference in the initial submission meaningfully strengthens the file. Attaching the Swerdloff et al. 2020 publication [3] alongside the FDA label [1] gives the clinical reviewer immediate access to the pharmacokinetic rationale for preferring an oral formulation when compliance with injections or topicals has been problematic. The Endocrine Society guideline [4] provides a standard-of-care anchor that most health plan medical directors recognize.

A 2021 analysis in the Journal of Managed Care and Specialty Pharmacy found that PA requests that included peer-reviewed literature citations had a first-pass approval rate approximately 18 percentage points higher than requests with clinical notes alone, though the absolute approval rates varied widely by drug class and plan type [9]. Including literature does not guarantee approval, but it materially reduces the probability of an initial denial on medical necessity grounds.

What Formulary Tier Is Jatenzo on Anthem Plans?

Jatenzo sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on which specific Anthem plan the patient holds. Anthem's commercial formulary structure varies by employer group, state, and whether the plan is a PPO, HMO, or EPO. Members should verify the exact tier by logging into their Anthem member portal and running a drug lookup with their specific plan ID, or by calling the pharmacy benefits number on the back of their insurance card [10].

On a typical Tier 4 benefit design, the member cost-share after meeting the deductible may range from 30% to 50% coinsurance or a fixed copay of $100 to $150 per 30-day supply, depending on whether the member uses a preferred specialty pharmacy. Some Anthem plans route specialty and high-cost branded medications through designated specialty pharmacy partners such as CuraScript or Walgreens Specialty Pharmacy, and using a non-designated pharmacy may result in a higher out-of-pocket cost or an outright benefit exclusion for that fill [10].

Testosterone replacement therapies as a class are not excluded from Anthem's commercial pharmacy benefit under the standard plan design for male hypogonadism, though certain self-funded employer plans have carved out specific hormonal therapies. Members on self-funded employer plans should ask their HR department whether any carve-outs apply before submitting a PA [11].

Step Therapy: Which Testosterone Agents Does Anthem Require First?

Anthem's step therapy protocol for testosterone replacement typically requires documented failure of or contraindication to at least one lower-cost testosterone formulation before Jatenzo is approved. The two most commonly required first-step agents on Anthem's formulary are generic testosterone cypionate injection and generic testosterone topical gel 1.62% or 1%, both of which cost substantially less at retail [6].

Testosterone cypionate is priced between $30 and $60 per 10 mL vial at most retail pharmacies when dispensed as a generic, compared with Jatenzo's approximate $900 monthly cost [6]. The cost differential is the core actuarial reason insurers impose step therapy. From a clinical perspective, the FDA's 2018 hypogonadism drug approval framework acknowledges that multiple formulations exist with similar efficacy endpoints, making formulary management of newer brand-only agents a standard commercial practice [12].

Physicians can bypass step therapy with appropriate clinical justification. Documented contraindications that Anthem typically accepts include: active polycythemia (hematocrit above 54%) that worsened on injection therapy, severe injection phobia confirmed in psychiatric or primary care notes, skin conditions such as contact dermatitis affecting topical absorption, and household transfer risk to a child under 12 years or a pregnant partner [7]. Each of these exceptions requires supporting documentation in the PA submission. Verbal statements alone are insufficient for the plan's medical necessity determination.

The Endocrine Society guideline explicitly states: "We suggest that clinicians consider the patient's preference, ease of use, pharmacokinetics, and formulation-related adverse effects when choosing among available testosterone preparations" [4]. That guidance gives prescribers a clinical-standards basis for arguing oral delivery preference in patients who have demonstrated non-adherence to injections or topicals during a prior trial.

How to Appeal an Anthem Denial of Jatenzo

Anthem denials for Jatenzo fall into two categories: medical necessity denials and step therapy non-completion denials. Each requires a slightly different appeal approach.

Step 1: Internal Appeal. Anthem allows one level of internal appeal, which must be filed within 180 days of the denial notice date on most commercial plans [8]. The appeal must include new or additional clinical information not submitted with the original PA. Submitting a peer-to-peer call request simultaneously with the written appeal is advisable because peer-to-peer conversations with Anthem's medical director have a documented reversal rate higher than written appeals alone [13].

Step 2: External / Independent Review. If the internal appeal is denied, the member or prescriber may request review by a state-approved Independent Review Organization (IRO). Under ACA Section 2719 and state insurance codes, IRO decisions are binding on the insurer [14]. The IRO process applies to medical necessity and clinical appropriateness disputes on all non-grandfathered commercial plans. Filing an IRO request typically requires completing a form from the state insurance commissioner's office or from Anthem directly [14].

Step 3: State Insurance Commissioner Complaint. If the IRO process is unavailable or the plan is a self-funded ERISA plan (where state IRO laws may not apply), the member may file a complaint with the U.S. Department of Labor's Employee Benefits Security Administration [15]. Self-funded plan appeals follow the ERISA internal and external claims review regulations at 29 CFR 2560.503-1 [15].

A 2019 study in Health Affairs found that patients who pursued external appeals for specialty drug denials succeeded in approximately 39% to 44% of cases, a rate high enough to make the appeal process worth completing in most situations where clinical documentation is strong [13].

Key documents to include in any Jatenzo appeal for Anthem:

• The original denial letter with the specific denial reason code
• Two morning testosterone lab values (both <300 ng/dL)
• LH and FSH results confirming hypogonadism subtype
• Documentation of prior testosterone agent trials with dates and discontinuation reasons
• Swerdloff et al. 2020 [3] and the Jatenzo FDA prescribing information [1]
• Endocrine Society 2018 guideline section on formulation selection [4]
• A signed letter of medical necessity from the prescribing physician

Can I Use the Jatenzo Manufacturer Savings Card With Anthem Coverage?

Clarus Therapeutics (the original developer) and the current Jatenzo commercial rights holder offer a savings card program for commercially insured patients. The savings card may reduce out-of-pocket costs to as low as $0 per fill for eligible patients, subject to a maximum annual benefit cap that varies by program year [16].

The card is not valid for patients whose primary or secondary coverage is a federal or state government program, including Medicare, Medicaid, TRICARE, or VA benefits [16]. Anthem commercial PPO and HMO members are generally eligible for the savings card, but eligibility must be confirmed at the pharmacy at the time of dispensing.

One practical consideration: using a manufacturer savings card for a medication that is not yet approved on your plan may still trigger a claim denial at the pharmacy benefit level, because the insurer will not adjudicate a claim for a drug that lacks an active PA authorization. The savings card reduces your copay on an approved claim; it does not substitute for PA approval. Patients who intend to use the savings card should still complete the PA process first, then apply the card to the approved, adjudicated claim [16].

Cash-Pay and Alternative Coverage Options

If Anthem denies Jatenzo and the appeal is unsuccessful, several options exist for obtaining the medication at a lower cost.

The current list price for Jatenzo is approximately $900 per month at retail pharmacies. GoodRx and similar discount programs do not typically generate substantial discounts on single-source brand medications like Jatenzo, though checking current GoodRx pricing at the specific dispensing pharmacy is worthwhile because prices vary by location [17].

Compounded oral testosterone is not FDA-approved as a substitute for Jatenzo and is not bioequivalent; the FDA has not approved any compounded oral testosterone undecanoate for commercial distribution in the United States [12]. Switching to an FDA-approved injectable or topical generic while continuing to appeal for Jatenzo coverage is the most common clinical strategy when a denial is pending. Generic testosterone cypionate 200 mg/mL provides established efficacy for hypogonadism at a fraction of the cost, and the Endocrine Society notes comparable testosterone normalization rates across formulations in adherent patients [4].

Some patients obtain Jatenzo coverage through employer-sponsored plans that list it differently in a carve-in formulary, or through an Anthem Medicare Advantage plan if their specific plan's Part D formulary includes it. Checking the Medicare Part D formulary lookup tool at CMS.gov for any Anthem-branded Medicare Advantage plan that covers the prescribing provider's service area may reveal a lower-tier placement [18].

Monitoring Requirements That Support Ongoing Coverage

Anthem's PA approvals for Jatenzo are typically granted for an initial 12-month period with renewal authorization required annually. Renewal PA submissions must include updated laboratory documentation confirming continued medical necessity and appropriate response to therapy [5].

The FDA prescribing information for Jatenzo requires monitoring of hematocrit at baseline, 3 to 6 months after initiation, and then annually [1]. Hematocrit above 54% requires dose reduction or temporary discontinuation. Anthem reviewers are increasingly checking that renewal submissions include this monitoring data, because the FDA label requirement creates a clear documentation standard [1].

The Endocrine Society recommends measuring total testosterone 3 to 6 months after initiating therapy, with a target mid-normal range (400 to 700 ng/dL in most laboratory reference ranges) [4]. Documenting that the patient's testosterone has normalized within the target range during a prior Jatenzo course is the strongest possible argument for renewal PA approval and reduces the risk of a renewal denial on efficacy grounds [4].

Blood pressure monitoring is also required with Jatenzo because oral testosterone undecanoate has been associated with increases in blood pressure that may require dose reduction or discontinuation [1]. The FDA added a black box warning regarding blood pressure to the Jatenzo label in 2021, and Anthem medical directors may request blood pressure logs or clinic visit notes confirming stable cardiovascular status at renewal [1].